Salmeterol: A study by Prescription Event Monitoring in a UK cohort of 15,407 patients

Mann, Ronald D.; Kubota, Kiyoshi; Pearce, Gillian; Wilton, Lynda V.

doi:10.1016/0895-4356(95)00555-2

Cited by 99 publications

(33 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…No studies have specifically examined the use of the long acting b 2 -agonists, such as salmeterol and eformoterol, either alone or in combination with ICS in asthmatics during pregnancy. An epidemiological study of salmeterol use in .15,000 patients, reported that among this population, there were 65 subjects who used salmeterol while pregnant [139]. While no adverse outcomes were reported, there was no information given about the analysis of outcomes or maternal asthma status, as this was not the primary aim of the study [139].…”

Section: The Treatment and Management Of Asthma During Pregnancymentioning

confidence: 99%

Asthma during pregnancy: mechanisms and treatment implications

Murphy

Gibson²,

Smith³

et al. 2005

Eur Respir J

159

View full text Add to dashboard Cite

Asthma is becoming increasingly prevalent worldwide. Numerous historical and prospective cohort studies have investigated the effects of maternal asthma on pregnancy outcome; however, the data has been conflicting and many studies have not used standard classifications for asthma severity. Overall, the literature suggests that asthmatic females are more at risk of low birth weight neonates, pre-term delivery and complications such as preeclampsia, especially in the absence of actively managed asthma treated with inhaled corticosteroids. Pregnancy with a female foetus may particularly increase the risk of these outcomes.In addition, pregnancy has an effect on the course of asthma. The risk of an exacerbation requiring medical intervention may be as high as 50% in females with severe asthma and this may further increase the risk of poor outcomes, particularly low birth weight and pre-term delivery.The mechanisms responsible for changes in asthma with pregnancy, or alterations in pregnancy outcomes due to asthma have not been thoroughly explored. Maternal inflammatory pathways may contribute to reduced foetal growth through alterations in placental function.Asthma treatment, by reducing maternal inflammation and preventing exacerbations, is safe for use in pregnant females and contributes to improved outcomes for both mother and foetus.

show abstract

Section: The Treatment and Management Of Asthma During Pregnancymentioning

confidence: 99%

Asthma during pregnancy: mechanisms and treatment implications

Murphy

Gibson²,

Smith³

et al. 2005

Eur Respir J

159

View full text Add to dashboard Cite

show abstract

“…A postmarketing surveillance study of formoterol in general practice in England showed no important side effect in 33 patients who took formoterol during pregnancy (Wilton and Shakir, 2002). Moreover, an epidemiologic study reported no adverse outcomes among 65 women who used salmeterol while pregnant (Mann et al, 1996). The use of LABAs as monotherapy was reported in one study that did not find any evidence of an effect on fetal growth in humans (Bracken et al, 2003).…”

Section: F Pregnancymentioning

confidence: 96%

Pharmacology and Therapeutics of Bronchodilators

Cazzola

Page

Calzetta

et al. 2012

Pharmacological Reviews

408

368

View full text Add to dashboard Cite

“…The interpretation of the study was questioned by SEARS and TAYLOR [9]. The complete study of 15 407 patients observed for over 1 year did not find that salmeterol was associated with asthma deaths [10].…”

Section: -Agonistsmentioning

confidence: 99%